Glass House Brands (GLAS) Capital Expenditures (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Capital Expenditures of -$3.5 million for Q1 2026, up 47.04% year-over-year from -$2.4 million in Q1 2025, and down 116.62% quarter-over-quarter from $21.3 million in Q4 2025.
Glass House Brands (GLAS) Capital Expenditures (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Capital Expenditures for 7 consecutive years, with -$3.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures rose 47.04% year-over-year to -$3.5 million; the TTM figure through Mar 2026 stood at -$293000.0 (down 104.88% YoY), while the FY2025 annual figure was -$3.4 million, down 133.44% from the prior year.
- Capital Expenditures retreated to -$3.5 million in Q1 2026 per GLAS's latest filing, from $21.3 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $21.3 million in Q4 2025 and bottomed at -$9.5 million in Q2 2025.
- Historically, Capital Expenditures has averaged $1.5 million across 5 years, with a median of -$1.4 million in 2024.
- Annual changes were most pronounced in 2022 — Capital Expenditures surged 1404.77% — and 2024, when it plunged 1999.03%.
- Glass House Brands' Capital Expenditures stood at $4.1 million in 2022, then jumped by 47.85% to $6.0 million in 2023, then jumped by 198.35% to $18.0 million in 2024, then increased by 18.35% to $21.3 million in 2025, then sank by 116.62% to -$3.5 million in 2026.
- Business Quant data shows GLAS's Capital Expenditures at -$3.5 million in Q1 2026, $21.3 million in Q4 2025, and -$8.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 104.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 117.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -337.60 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 108.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 52.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 7.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 33.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Glass House Brands | 837.25 Mn | 818.69 Mn | 15.77 Mn | -2.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.55 Mn |
| Mar 31, 2026 | -3.55 Mn |
| Dec 31, 2025 | 21.34 Mn |
| Dec 31, 2025 | 21.34 Mn |
| Sep 30, 2025 | -8.63 Mn |
| Sep 30, 2025 | -8.63 Mn |
| Jun 30, 2025 | -9.46 Mn |
| Jun 30, 2025 | -9.46 Mn |
| Mar 31, 2025 | -6.70 Mn |
| Mar 31, 2025 | -6.70 Mn |
| Dec 31, 2024 | 18.03 Mn |
| Dec 31, 2024 | 18.03 Mn |
| Sep 30, 2024 | -1.42 Mn |
| Sep 30, 2024 | -1.42 Mn |
| Jun 30, 2024 | -3.91 Mn |
| Jun 30, 2024 | -3.91 Mn |
| Mar 31, 2024 | -2.41 Mn |
| Mar 31, 2024 | -2.41 Mn |
| Dec 31, 2023 | 6.04 Mn |
| Dec 31, 2023 | 6.04 Mn |